CAH-Adrenal Laboratory News

In a new paper from Neurocrine Biosciences, CHLA’s Dr. Mimi Kim and collaborators explore using the drug crinecerfont to treat congenital adrenal hyperplasia.

Poster session finalists were voted on by a scientific committee and presented key takeaways from their research during Science Day 2024.

Findings from the novel study suggest that congenital adrenal hyperplasia begins to affect brain development in the womb.

Mitchell Geffner, MD, received the 2022. International Outstanding Clinician Award from the European Society for Paediatric Endocrinology.

Youth with congenital adrenal hyperplasia (CAH) often develop cardiovascular disease risk factors such as obesity and hypertension. Carotid intima-media thickness (CIMT), a marker of cardiovascular